Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 63-2521 dose-titration study in symptomatic pulmonary arterial hypertension
NL-OMON35306Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of riociguat in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Bayer. Primary endpoint: Change from baseline in 6-minute walking distance. Started Jan 2009; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON35306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35306.